An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer.

Sponsor:

AstraZeneca

Sponsor Study ID:

D781DC00001

CTO #:

104225

NCT Number:

NCT06989112

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Other Female Genital

Study Objectives:

To demonstrate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd + pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by blinded independent central review (BICR), in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)